Form 4: Director Steve Krognes Sells Guardant Health Shares

Director Steve Krognes sold 9,294 shares of Guardant Health, Inc. common stock on June 4, 2026.

Summary

• Director Steve Krognes executed a sale of 9,294 shares of Guardant Health (GH) common stock.
• The shares were sold at a weighted average price of $132.5072 per share.
• The transaction occurred on June 4, 2026.
• Following the sale, the reporting person retains beneficial ownership of 10,222 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine disclosure of an insider transaction without accompanying negative operational news.

Positives

• The transaction was executed at a high price point of approximately $132.51 per share, reflecting current market valuation.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term share price appreciation.

Risks

• Market volatility affecting the share price of Guardant Health.

Future Outlook

No specific forward-looking guidance or operational outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that insider sales by directors are common occurrences for portfolio rebalancing or liquidity needs and do not necessarily reflect a negative outlook on the company's core business performance.

Comparison to Industry Standards

• Insider transactions are standard regulatory disclosures for publicly traded companies in the biotechnology sector.
• The sale volume represents a partial divestment rather than a total exit, which is consistent with typical director equity management.

Stakeholder Impact

• Shareholders should note the change in insider ownership levels.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Guardant Health, GH, Insider Trading, Form 4, Steve Krognes, Biotech